Related Experiment Video
Updated: May 14, 2026

Synthesis and Assay of Vibrio Quorum Sensing Inhibitors
Published on: May 31, 2024
Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states
Anjali K Struss1, Ashlee Nunes, Jill Waalen
1Departments of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.
Abstract:
The opportunistic bacterial pathogen Pseudomonas aeruginosa causes chronic lung infections in cystic fibrosis (CF) patients. Importantly, virulence factor expression and biofilm formation in P. aeruginosa is coordinated by quorum sensing (QS) and one of the key QS signaling molecules is 3-oxo-C12-HSL. Remarkably, a tetramic acid, (C12-TA), with antibacterial properties is formed spontaneously from 3-oxo-C12-HSL under physiological conditions. Seeking to better understand this relationship, we sought to investigate whether 3-oxo-C12-HSL and C12-TA may be contributing factors to the overall pathogenicity of P. aeruginosa in CF individuals and if their detection and quantitation in sputum samples might be used as an indicator to assess disease states and monitor therapy success in CF patients. To this end, 3-oxo-C12-HSL and C12-TA concentrations were initially analyzed in P. aeruginosa flow cell biofilms using liquid chromatography coupled with mass spectrometry (LC-MS). A liquid chromatography tandem mass spectrometry (LC-MS/MS)-based method was then developed and validated for their detection and quantification in the sputa of CF patients. To the best of our knowledge, this is the first report to show the presence of both the quorum sensing molecule (3-oxo-C12-HSL) and its rearranged product (C12-TA) in human clinical samples such as sputum. A total of 47 sputum samples from 20 CF and 2 non-CF individuals were analyzed. 3-Oxo-C12-HSL was detected and quantified in 45 samples with concentrations ranging from 20 to >1000 nM; C12-TA was found in 14 samples (13-900 nM). On the basis of our findings, quorum sensing autoinducers merit further investigation as biomarkers for infectious disease states.
Insights
Pseudomonas aeruginosa quorum sensing molecule 3-oxo-C12-HSL and its byproduct C12-TA were detected in cystic fibrosis patient sputum. These molecules may serve as biomarkers for infection severity and treatment monitoring.
Area of Science:
- Microbiology
- Clinical Chemistry
- Biochemistry
Background:
- Pseudomonas aeruginosa is an opportunistic pathogen causing chronic lung infections in cystic fibrosis (CF) patients.
- Quorum sensing (QS) regulates virulence and biofilm formation in P. aeruginosa, with 3-oxo-C12-HSL as a key signaling molecule.
- 3-oxo-C12-HSL can spontaneously form an antibacterial tetramic acid (C12-TA) under physiological conditions.
Purpose of the Study:
- To investigate the role of 3-oxo-C12-HSL and C12-TA in P. aeruginosa pathogenicity in CF patients.
- To determine if these molecules can be quantified in sputum as indicators of disease state and therapeutic success.
Main Methods:
- Analysis of 3-oxo-C12-HSL and C12-TA concentrations in P. aeruginosa biofilms using liquid chromatography-mass spectrometry (LC-MS).
- Development and validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for detecting and quantifying these molecules in CF patient sputum.
- Analysis of 47 sputum samples from CF and non-CF individuals.
Main Results:
- 3-oxo-C12-HSL was detected in 45 out of 47 sputum samples (20-1000+ nM).
- C12-TA was found in 14 samples (13-900 nM).
- This is the first report of both 3-oxo-C12-HSL and C12-TA in human clinical samples like sputum.
Conclusions:
- Quorum sensing autoinducers 3-oxo-C12-HSL and C12-TA are present in CF patient sputum.
- These molecules show potential as biomarkers for assessing infectious disease states in CF patients.
- Further investigation of QS autoinducers as biomarkers for infectious diseases is warranted.
More Related Videos
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Bacterial Signaling
Microbial Biosensors
Automated Microbial Diagnostics

